

Abcam acquires EdiGene's Knock-out cell lines and Lysates Portfolio

17 July 2019 | News

Using their proprietary high throughput cell editing platform, EdiGene developed the industry's largest off-the shelf diploid library of over 2,800 single clonal knockout (KO) cell lines



Abcam plc, a global innovator in life science reagents and tools, is pleased to announce the acquisition of the entire live cell line and lysates portfolio of China based EdiGene Inc, a leading company focused on developing genome editing technologies into novel therapeutics for a broad range of diseases and into creative solutions to advance drug discovery.

Using their proprietary high throughput cell editing platform, EdiGene developed the industry's largest off-the shelf diploid library of over 2,800 single clonal knockout (KO) cell lines targeting over 2,600 genes in commonly used human cancer cell lines (including HeLa, HEK293-T, A549, HCT116, Hep G2 and MCF7).

Ready-made diploid KO cell-lines are an important tool for antibody validation. They also play a significant role in the study and understanding of biological pathways and disease models and can be used in screening and cellular assays. EdiGene's cell lines and lysates are used by top academic researchers, global biopharmaceutical companies, and leading antibody companies.

The lysate range is expected to be available through the Abcam website in early Q4 2019, with the expanded cell line offering following throughout 2020. In addition, these products will be used to support further knock-out antibody validation, an integral part of Abcam's on-going antibody quality initiative.